Clinical Trial: Clinical Study of Chemogenetic Gene Therapy With AAV Virus for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07533591) titled 'Clinical Study of Chemogenetic Gene Therapy With AAV Virus for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus' on April 09.

Brief Summary: The investigators propose a gene therapy strategy for Parkinson's disease - a chemogenetic inhibition technique to intervene in the abnormal activity of the subthalamic nucleus in Parkinson's patients. The investigators design and construct a therapeutic injection agent called STP-001, through an efficient adeno-associated virus capsid (AAV), a neuronal promoter (hSyn), and a chemogenetic effector element (hM4Di). Then, the drug was accurately injected into the bilater...